Form 4: MANGOCEUTICALS CFO Granted 100,000 Shares

MANGOCEUTICALS, INC. Chief Financial Officer Eugene M. Johnston received a grant of 100,000 shares of common stock as compensation.

Summary

• Eugene M. Johnston, Chief Financial Officer of MANGOCEUTICALS, INC. (MGRX), was granted 100,000 shares of common stock.
• The shares were issued on September 9, 2025, at a price of $0 per share, indicating a grant rather than a purchase.
• This grant was made in consideration for his service as CFO and falls under the company's Second Amended and Restated 2022 Equity Incentive Plan, as amended.
• Following this transaction, Mr. Johnston beneficially owns a total of 138,334 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of shares to a key executive is generally a positive sign of commitment and aligns interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of shares aligns the Chief Financial Officer's interests with those of shareholders, potentially incentivizing long-term performance and commitment to the company's success.
• Issuance under an existing equity incentive plan demonstrates a structured and pre-approved approach to executive compensation.

Negatives

• The grant of 100,000 shares, while a form of compensation, represents an increase in the total number of outstanding shares, which can lead to minor dilution for existing shareholders.

Future Outlook

NA

Industry Context

This transaction is a routine executive compensation event and does not provide specific insights into broader industry trends or competitive dynamics beyond the company's internal compensation practices.

Related Party Transactions

• The grant of 100,000 shares of common stock to Eugene M. Johnston, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential minor dilution from the issuance of new shares, but also increased alignment of executive interests with shareholder value.
• Employees: Demonstrates the company's use of equity compensation to reward key personnel.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to the Chief Financial Officer as part of their compensation package. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for MANGOCEUTICALS, INC. Therefore, a 'hold' recommendation is appropriate as this event alone is unlikely to drive significant stock price movement or warrant a change in existing positions.

Keywords

MANGOCEUTICALS, MGRX, Eugene M. Johnston, CFO, Stock Grant, Equity Incentive Plan, Beneficial Ownership, Executive Compensation, Form 4, SEC Filing